Aldesleukin 22000000 UNT Injection [Proleukin]

Known as: ALDESLEUKIN 1.1 mg in 1 mL INTRAVENOUS INJECTION [PROLEUKIN], Proleukin 22,000,000 UNT Injection, aldesleukin 1.1 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Proleukin] 
 
National Institutes of Health

Related topics

Related topics

8 relations
AldesleukinInjectionMannitolProleukin
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
Regulatory T cells (Tregs) play an important role in preventing effector T-cell (Teff) targeting of self-antigens that can lead… (More)
Is this relevant?
2014
2014
A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
A multi-center study of high dose Aldesleukin (Proleukin®(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF… (More)
  • figure 1
Is this relevant?
2014
2014
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
Prometheus Laboratories, San Deigo, CA, USA Full list of author information is available at the end of the article Figure 1 Open… (More)
  • figure 1
Is this relevant?
2011
2011
Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2.
BACKGROUND The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of… (More)
Is this relevant?
2007
2007
Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model.
BACKGROUND Local therapy with IL-2 may be very effective in the treatment of different forms of cancer. The aim of this study was… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Comparison of Pharmacokinetics and Pharmacodynamics of two different dosing regimens of Proleukin® (IL-2) in Combination with rituximab: The effect of NK cell expansion.
 
Is this relevant?
2004
2004
Investigation of FcγR Polymorphisms and Response to IL-2 (Proleukin®) and Rituximab Treatment in Rituximab-Resistant NHL Patients: Importance of the F/F Polymorphism at Position 158 of the Fcγ.
 
Is this relevant?
2004
2004
First-line-Therapie für deutsche Patienten mit metastasiertem Nierenzellkarzinom im EORTC-Protokoll 30012
Die AUO nimmt derzeit aktiv an der internationalen EORTC-Studie 30012, A Randomized Controlled Trial of Interferon-α, Interleukin… (More)
Is this relevant?
2001
2001
Persistierende knotige Lokalreaktion mit Lymphom-ähnlichen Infiltraten nach s.c-Injektion von Interleukin-2
Interleukin-2 (IL-2) kommt aufgrund seiner immunstimulatorischen Wirkung auf T-Zellen in der Tumortherapie von Karzinomen, Leuk… (More)
Is this relevant?